Beth Israel Deaconess Medical Center (BIDMC) is a major teaching hospital of Harvard Medical School. The BIDMC oncology faculty consists of an exceptional group of committed basic and clinical investigators. BIDMC is home to nationally recognized centers of expertise focused on breast cancer, melanoma, renal cancer, prostate cancer, ovarian cancer, pancreatic cancer, hepatic cancer and hematologic malignancies. Areas of renowned scientific expertise include: vaccine and cytokine therapy, angiogenesis Inhibition and targeted therapy. In 1999, the BIDMC participated in the founding of the Dana-Farber/Harvard Cancer Center (DF/HCC), which includes ail Harvard Medical School affiliated Institutions. This arrangement enables the leveraging of scientific and clinical cancer research expertise across all Harvard institutions, enabling the creation of translational and clinical research entities. For example, since its founding, the DF/HCC has successfully competed for 8 SPORE grants (Breast, Skin, Kidney, Prostate, Ovarian, Myeloma and Lung), with BIDMC investigators being active participants in virtually all of these. Cancer clinical trials support is provided by a dedicated Cancer Clinical Trials Office (CCTO) which provides regulatory, administrative, educational and quality assurance support for 11 disease-based multi-disciplinary clinical research programs. BIDMC has been a main ECOG institution since 1997 and has been a main institution since 1998. Over the initial 11 years of funding, BIDMC investigators have consistently recruited 40-80 patients per year to therapeutic and prevention trials. To date, in 2009, BIDMC has accrued 30 patients to therapeutic trials. The BIDMC ECOG grant supports 3 affiliate institutions. BIDMC investigator scientific and administrative participation in ECOG activities, data quality, data delinquency rates and affiliate accrual have all steadily increased over the past funding period. With the transition of research protocols to DF/HCC IRB and the creation of CCTO infrastructure now complete, the BIDMC stands poised to enhance our laboratory and clinical research contributions and increase our participation in ECOG related activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA080775-14
Application #
8262137
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1999-05-12
Project End
2014-02-28
Budget Start
2012-05-01
Budget End
2014-02-28
Support Year
14
Fiscal Year
2012
Total Cost
$95,411
Indirect Cost
$40,577
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Hodi, F Stephen; Lee, Sandra; McDermott, David F et al. (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744-53
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Dutcher, Janice P; Neuberg, Donna; Atkins, Michael B et al. (2014) Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution. J Interferon Cytokine Res 34:376-84
Liu, Glenn; Chen, Yu-Hui; Kolesar, Jill et al. (2013) Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol 31:211-8
Karp, Daniel D; Lee, Sandra J; Keller, Steven M et al. (2013) Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol 31:4179-87
Liu, Glenn; Chen, Yu-Hui; Dipaola, Robert et al. (2012) Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 10:99-105
Solin, Lawrence J; Gray, Robert; Goldstein, Lori J et al. (2012) Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat 134:683-92
Greenberg, Peter L; Sun, Zhuoxin; Miller, Kenneth B et al. (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393-400
Atkins, Michael B; Hsu, Jessie; Lee, Sandra et al. (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordin J Clin Oncol 26:5748-54
Stuart, Keith; Levy, Donna E; Anderson, Tom et al. (2004) Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs 22:75-81

Showing the most recent 10 out of 13 publications